title: Molecular docking of chemotherapeutic agents to CYP3A4 in non-small cell lung cancer.
abstract: CYP3A4, a "heme" containing isoform, abundantly found in the liver, gastro-intestinal tract, lungs and renal cells, also known as drug metabolising enzyme (DME) may be responsible for the disease progression in cancers such as lung cancer. Hence, we have targeted this protein for improving drug selection and in preventing adverse reactions. The aim of this study was to examine chemotherapeutic drug binding to CYP3A4 and the interactions therein. We have used Schrödinger suite 2014, to perform molecular docking of human CYP3A4, by Induced Fit Docking using gemcitabine, cisplatin, carboplatin, docetaxel and paclitaxel drugs. We evaluated drug-binding affinities using Prime/MMGBSA and using these scores we compared the affinities of combination therapies against CYP3A4. Analysis of the docking results showed gemcitabine>carboplatin>cisplatin as the order of binding affinities, with gemcitabine having the best docking score. Interestingly, docetaxel and paclitaxel did not bind to CYP3A4*1B. The combination drug-binding affinity analysis showed gemcitabine+carboplatin to have the best docking score and hence, efficacy. Our investigation has identified the residue Arg 105 to be more frequently involved in drug binding to CYP3A4. Our results suggest that gemcitabine or combination of gemcitabine+carboplatin could serve as an excellent therapy against CYP3A4 in NSCLC patients. Thus, our study depicts binding of chemotherapeutic drugs to CYP3A4 and has identified the residues that may be targeted for therapy in NSCLC patients.
authors.affiliation: Genetics Department, Bhagwan Mahavir Medical Research Centre, Telangana, India.
authors.forename: Syed
authors.initials: S
authors.lastname: Subhani
authors.affiliation: Genetics Department, Bhagwan Mahavir Medical Research Centre, Telangana, India. Electronic address: kj.bmmrc@gmail.com.
authors.forename: Kaiser
authors.initials: K
authors.lastname: Jamil
mesh_terms: D000970:Antineoplastic Agents / Q000737:chemistry / Q000378:metabolism* / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy / Q000201:enzymology*; D018360:Crystallography, X-Ray; D051544:Cytochrome P-450 CYP3A / Q000737:chemistry / Q000378:metabolism*; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000201:enzymology*; D062105:Molecular Docking Simulation / Q000379:methods*; D017433:Protein Structure, Secondary
chemical_list: D000970:Antineoplastic Agents; D051544:Cytochrome P-450 CYP3A; C510163:CYP3A4 protein, human
keywords: Binding affinity; CYP3A4; Chemotherapeutics; Drug metabolism; Non-small cell lung cancer